Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)
QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.
Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.
The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.
Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.
This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.
Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Ipsen Clinical Study Enquiries
- 电话号码:See email
- 邮箱:clinical.trials@ipsen.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.
描述
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
- Males ≥18 years old.
- Patient with histologically confirmed PCa.
- Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
- Patient able to understand and complete study-related questionnaires.
- Patient having been informed and not opposed to participating in the study.
- Patient covered by healthcare insurance.
Exclusion Criteria
Patients will not be included in the study if they meet any of the following criteria:
- Patient currently participating in any interventional clinical trial.
- Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
- Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
大体时间:At 6 months
|
At 6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Participants' baseline demographic characteristics
大体时间:At baseline
|
Including:
|
At baseline
|
|
Participants' clinical characteristics at baseline
大体时间:At baseline
|
Including:
|
At baseline
|
|
Prostate cancer characteristics at diagnosis and baseline
大体时间:At baseline
|
Including:
|
At baseline
|
|
Participants symptoms at baseline
大体时间:At baseline
|
At baseline
|
|
|
Participants' PCa treatment patterns at baseline
大体时间:At baseline
|
|
At baseline
|
|
Participants' healthcare pathway/supportive care done or planned
大体时间:At baseline
|
Including:
|
At baseline
|
|
Evolution of PCa at 6-month follow-up according to investigator's opinion
大体时间:At 6 months
|
Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression. |
At 6 months
|
|
Symptoms and biological characteristics at 6 months
大体时间:At 6 months
|
At 6 months
|
|
|
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
大体时间:At 6 months
|
The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity. |
At 6 months
|
|
Participants' Quality Of life (QoL)
大体时间:At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' PCa treatment patterns at 6 months
大体时间:At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' healthcare pathway/supportive care at 6 months
大体时间:At 6 months
|
• Participant's healthcare pathway/type of supportive care in case of changes. |
At 6 months
|
|
Identification of factors associated with participant's quality of life
大体时间:At 6 months
|
• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model. |
At 6 months
|
|
Percentage of participants with adverse events
大体时间:From enrollment to Month 6
|
An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up. |
From enrollment to Month 6
|
合作者和调查者
赞助
调查人员
- 研究主任:Ipsen Medical Director、Ipsen
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CLIN-52014-030
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 共享时间框架
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 共享访问标准
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.